B
Bengt I. Eriksson
Researcher at University of Gothenburg
Publications - 216
Citations - 25934
Bengt I. Eriksson is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Dabigatran & Low molecular weight heparin. The author has an hindex of 75, co-authored 216 publications receiving 24111 citations. Previous affiliations of Bengt I. Eriksson include Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.
Sam Schulman,U. Angerås,David Bergqvist,Bengt I. Eriksson,Michael R. Lassen,William D. Fisher +5 more
TL;DR: A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
Journal ArticleDOI
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson,Lars C. Borris,Richard J. Friedman,Sylvia Haas,Menno V. Huisman,Ajay K. Kakkar,Tiemo J. Bandel,Horst Beckmann,Eva Muehlhofer,Frank Misselwitz,William Geerts +10 more
TL;DR: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once- daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty.
Journal ArticleDOI
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C Niek van Dijk,Simon P. Frostick,Martin H. Prins,Rohan Hettiarachchi,Stefan Hantel,Janet Schnee,Harry R. Büller +10 more
TL;DR: Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile.
Journal ArticleDOI
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar,Benjamin Brenner,Ola E. Dahl,Bengt I. Eriksson,Patrick Mouret,James Muntz,Andrea G. Soglian,Akos F. Pap,Frank Misselwitz,Sylvia Haas +9 more
TL;DR: Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty.
Journal ArticleDOI
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C. N. Van Dijk,Simon P. Frostick,Peter Kälebo,Anita Vedel Christiansen,Stefan Hantel,Rohan Hettiarachchi,Janet Schnee,Harry R. Büller +11 more
TL;DR: Dabigatran etexilate (220 mg or 150‰mg) was at least as effective as enoxaparin and had a similar safety profile for prevention of VTE after total knee replacement surgery.